Affordable Access

deepdyve-link
Publisher Website

Current Perspective of Antiviral Strategies against COVID-19.

Authors
  • Ahidjo, Bintou A1, 2, 3
  • Loe, Marcus Wing Choy2, 3
  • Ng, Yan Ling2, 3
  • Mok, Chee Keng1, 2, 3
  • Chu, Justin Jang Hann1, 2, 3, 4
  • 1 NUSMed Biosafety Level 3 Core Facility, Yong Loo Lin School of Medicine, National University of Singapore, 14 Medical Drive, Singapore 117599, Singapore. , (Singapore)
  • 2 Laboratory of Molecular RNA Virology and Antiviral Strategies, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, 5 Science Drive 2, Singapore 117545, Singapore. , (Singapore)
  • 3 Infectious Disease Programme, Yong Loo Lin School of Medicine, National University of Singapore, 10 Medical Drive, Singapore 117597, Singapore. , (Singapore)
  • 4 Collaborative and Translation Unit for HFMD, Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR), Singapore 138673, Singapore. , (Singapore)
Type
Published Article
Journal
ACS Infectious Diseases
Publisher
American Chemical Society
Publication Date
Jun 16, 2020
Identifiers
DOI: 10.1021/acsinfecdis.0c00236
PMID: 32485102
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

COVID-19 was declared a pandemic by the World Health Organization on March 11, 2020. This novel coronavirus disease, caused by the SARS-CoV-2 virus, has resulted in severe and unprecedented social and economic disruptions globally. Since the discovery of COVID-19 in December 2019, numerous antivirals have been tested for efficacy against SARS-CoV-2 in vitro and also clinically to treat this disease. This review article discusses the main antiviral strategies currently employed and summarizes reported in vitro and in vivo efficacies of key antiviral compounds in use.

Report this publication

Statistics

Seen <100 times